Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00413114 | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS) | PHASE2 | COMPLETED | 24 | — | — | Dec 1, 2006 | Nov 1, 2009 | Aug 26, 2013 | 22 | United States, Canada |
Determine the response rate according to bone marrow blast count less than or equal to 10%
| Arm | Type | Description |
|---|---|---|
| Obatoclax Mesylate | EXPERIMENTAL | Obatoclax Mesylate 30mg |
| Name | Type | Description |
|---|---|---|
| Obatoclax mesylate (GX15-070MS) | DRUG | - |
Inclusion Criteria: * Pathological confirmation of Myelodysplastic Syndromes (MDS) * Patients must have had no prior systemic therapy * Must have normal organ functions * Must have the ability to understand and willingness to sign a written informed consent form Exclusion Criteria: * Must not be ...